Shalby Q4 FY26 Results: Revenue, PAT, Net Profit and Key Highlights

Shalby Q4 FY26 results were declared on May 27, 2026. The company reported Rs 18.3 crore for the quarter ended March 31, 2026. Revenue from operations was Rs 290 crore. Results are on a consolidated basis. Shalby is a leading Multi-Specialty Hospitals and Orthopaedics company listed on Indian stock exchanges.

Click Here – Get Free Investment Predictions

Shalby Q4 FY26 Financial Highlights

Metric	Q4 FY26	Q4 FY25	YoY Change
Revenue from Operations (Rs Cr)	290	N/A	N/A
Net Profit (PAT) (Rs Cr)	18.3	11	N/A
Reporting Basis	Consolidated

Note: Q4 FY26 PAT Rs 18.3 Cr (vs Net Loss Rs 11 Cr in Q4 FY25) , strong turnaround. Revenue Rs 290 Cr. Healthcare volumes recovery drove profitability. Always verify from BSE/NSE audited filings before investment decisions.

Shalby Q4 FY26 Performance Analysis

The Shalby Q4 FY26 results reflect performance in the January to March 2026 quarter. Revenue stood to Rs 290 crore. The results reflect consistent operational execution. Shalby operates in the Multi-Specialty Hospitals and Orthopaedics sector and demonstrated resilience amid India’s GDP growth above 6.5% in FY26.

India’s macroeconomic backdrop in Q4 FY26 was characterised by sustained GDP growth, government capex of Rs 11.21 lakh crore for FY27, and the RBI’s accommodative policy stance. These factors supported credit availability and consumer demand, benefiting the Multi-Specialty Hospitals and Orthopaedics sector during the January to March 2026 quarter.

Key Business Factors in Q4 FY26

Revenue and Volume Performance

Revenue from operations in Shalby Q4 FY26 stood to Rs 290 crore. Steady execution supported the revenue performance. The Multi-Specialty Hospitals and Orthopaedics sector benefited from India’s domestic demand recovery and infrastructure push in FY26.

Profitability and Margin Trajectory

Q4 FY26 PAT of Rs 18.3 crore reflects the current operating environment in the Multi-Specialty Hospitals and Orthopaedics sector.

Sector and Macro Backdrop

India’s macro environment in Q4 FY26 was characterised by GDP growth above 6.5%, budgeted central capex of Rs 11.21 lakh crore for FY27, and the RBI’s accommodative policy stance. These factors supported business investment and consumer spending. The Multi-Specialty Hospitals and Orthopaedics sector benefited from these structural tailwinds during the quarter ended March 31, 2026.

Dividend Details

No dividend was declared for Q4 FY26. The company channelled cash towards operational growth and balance sheet strength in Q4 FY26.

FY27 Outlook

Following the Shalby Q4 FY26 results, investors will focus on management guidance for FY27 covering revenue growth, margin improvement, capital allocation, and order book health. Stable Q4 FY26 execution supports a constructive FY27 outlook. India’s GDP growth trajectory, domestic demand, and sector-specific catalysts will be key drivers for Shalby in FY27.

Shalby Stock Performance

Download the Univest iOS App or Univest Android App to track live price and daily stock recommendations.

Shares of Shalby are listed on NSE and BSE. Following the Q4 FY26 results on May 27, 2026, investors should monitor post-results price action, institutional activity, and management commentary. Always consult a SEBI-registered financial advisor before investment decisions.

Key Risks

Input Cost and Margin Volatility

Fluctuations in raw material costs, energy prices, and logistics expenses pose margin risks for Shalby in FY27. Any cost escalation without corresponding pricing power could compress EBITDA margins from Q4 FY26 levels.

Demand and Revenue Slowdown Risk

Any deceleration in India’s GDP growth, reduction in government capex, or weakening of private consumption could impact demand for Shalby’s products and services in the Multi-Specialty Hospitals and Orthopaedics sector in FY27.

Regulatory and Competitive Risk

Changes in regulatory frameworks, competitive pricing pressure from domestic and global peers, and customer concentration risks are key watchpoints for Shalby investors. Sustained execution against strategic priorities remains critical.

Conclusion

Shalby Q4 FY26 results declared on May 27, 2026 showed revenue of Rs 290 crore. The results reinforce the company’s execution capability heading into FY27. Investors should monitor management guidance, sector trends, and macroeconomic developments before making investment decisions.

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Verify all data from BSE/NSE audited filings.

Frequently Asked Questions on Shalby Q4 FY26 Results

What is Shalby Q4 FY26 net profit?

Ans. Shalby Q4 FY26 net profit was Rs 18.3 crore, N/A YoY vs Rs 11 crore in Q4 FY25. Results declared May 27, 2026 on consolidated basis.

What is Shalby Q4 FY26 revenue?

Ans. Shalby Q4 FY26 revenue was Rs 290 crore.

When were Shalby Q4 FY26 results declared?

Ans. Shalby Q4 FY26 results were declared on May 27, 2026 at the board meeting approving audited financial statements for the quarter ended March 31, 2026.

What dividend did Shalby declare for FY26?

Ans. No dividend was declared for Q4 FY26. Verify from BSE/NSE filings for record date and payout schedule.

What is the FY27 outlook for Shalby?

Ans. Following Shalby Q4 FY26 results, management guidance on revenue growth, margin improvement, and capital allocation shapes FY27 expectations. Consult a SEBI-registered advisor before investing.

Is Shalby a good buy after Q4 FY26 results?

Ans. Investment in Shalby requires assessment of fundamentals, valuation, sector outlook, and personal risk tolerance. This article is for educational purposes only. Consult a SEBI-registered financial advisor.

What sector does Shalby operate in?

Ans. Shalby operates in the Multi-Specialty Hospitals and Orthopaedics sector. The company is listed on Indian stock exchanges and declared Q4 FY26 results on May 27, 2026.